<p> Studies AdvanceMed Research has conducted that have received FDA approval</p><p>2012 </p><p>Bio-T-Gel (testosterone gel); Teva Pharmaceuticals; For the treatment of hypogonadism, Approved February 2012</p><p>Myrbetriq (mirabegron); Astellas Pharma US, Inc.; For the treatment of overactive bladder, Approved June 2012 </p><p>Stendra (avanafil); Vivus; For the treatment of erectile dysfunction, Approved April 2012</p><p>Xtandi (enzalutamide); Medivation; For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012</p><p>2011</p><p>Anturol (oxybutynin) Gel; Antares Pharma; For the treatment of overactive bladder, Approved December 2011 </p><p>Zytiga (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer, Approved May 2011</p><p>2010 </p><p>Fortesta (testosterone gel); Endo Pharmaceuticals; For the treatment of hypogonadism, Approved December 2010 </p><p>Jalyn (dutasteride + tamsulosin); GlaxoSmithKline; For the treatment of benign prostatic hyperplasia, Approved June 2010</p><p>Jevtana (cabazitaxel); sanofi aventis; For the treatment of prostate cancer, Approved June 2010</p><p>Provenge (sipuleucel-T); Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010 </p><p>Xgeva (denosumab); Amgen; For the prevention of skeletal-related events in patients with bone metastases from solid tumors, Approved November 2010</p><p>2009 </p><p>Gelnique (oxybutynin chloride); Watson Pharmaceuticals; For the treatment of overactive bladder, Approved January 2009</p><p>2008</p><p>D:\Docs\2018-02-07\0cfe3c087adba993035150a29d7fdfe0.doc Page 1 of 3 Studies AdvanceMed Research has conducted that have received FDA approval</p><p>Toviaz (fesoterodine fumarate); Pfizer; For the treatment of overactive bladder, Approved October 2008</p><p>Degarelix (degarelix for injection); Ferring Pharmaceuticals; For the treatment of prostate cancer, Approved December of 2008</p><p>Degarelix (degarelix for injection); Ferring Pharmaceuticals; For the treatment of prostate cancer, Approved December of 2008</p><p>2005</p><p>No approvals recorded for Urology in 2005. </p><p>2004</p><p>Sanctura (trospium chloride); For the treatment of overactive bladder with symptoms of urge urinary incontinence; Indevus Pharmaceuticals; Approved May, 2004</p><p>Vesicare (solifenacin succinate); For the treatment of overactive bladder with symptoms of urge urinary incontinence; Yamanouchi, GlaxoSmithKline; Approved November, 2004 </p><p>2003</p><p>Oxytrol (oxybutynin transdermal system); For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.; Watson Pharmaceuticals; Approved March 2003</p><p>UroXatral (alfuzosin HCl extended-release tablets); For the treatment of of the signs and symptoms of benign prostatic hyperplasia; Sanofi-Synthelabo; Approved June 2003</p><p>Crestor (rosuvastatin calcium); AstraZeneca; For the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia, Approved August 2003</p><p>Levitra (vardenafil); Bayer, GlaxoSmithKline; For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003</p><p>2002</p><p>Eligard (leuprolide acetate); For the palliative treatment of advanced prostate cancer; Atrix Laboratories; Approved January 2002 </p><p>2001</p><p>D:\Docs\2018-02-07\0cfe3c087adba993035150a29d7fdfe0.doc Page 2 of 3 Studies AdvanceMed Research has conducted that have received FDA approval</p><p>Dutasteride; For the treatment of symptomatic benign prostatic hyperplasia; GlaxoSmithKline; Approved November 2001 </p><p>2000</p><p>Detrol LA (tolterodine tartrate); For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency; Pharmacia & Upjohn; Approved December 2000 </p><p>1999</p><p>Ditropan XL (oxybutynin chloride); Treatment for overactive bladder; Alza; Approved June 1999 </p><p>1998</p><p>Detrol tablets; Treatment for an overactive bladder; Pharmacia & Upjohn; Approved March 1998 </p><p>Ditropan XL Tablets; Treatment for and Overactive Bladder; Alza; Approved December 1998 </p><p>Proscar; Treatment for complication relating to benign prostatic hyperplasia (BPH); Merck; Approved April 1998 </p><p>D:\Docs\2018-02-07\0cfe3c087adba993035150a29d7fdfe0.doc Page 3 of 3</p>